1 - LDL-C AND CVD
2 - HDL AND CVD
3 - TRIGLYCERIDES AND CVD
4 - DIABETES AND PLASMA LIPIDS
5 - INSULIN RESISTANCE, DIABETES, AND CVD
6 - LIPID LOWERING DRUGS AND MULTIPLE RISK
7 - HYPOLIPIDEMIC TREATMENT
8 - BILE ACID AND CHOLESTEROL ABSORPTION INHIBITORS
9 - PLEIOTROPIC EFFECTS OF STATINS: MOLECULAR MECHANISMS AND CLINICAL RELEVANCE
10 - COMBINED TREATMENT OF CVD
11 - CARDIOVASCULAR RISK IN THE ELDERLY
12 - MENOPAUSE AND CVD
13 - HRT
14 - OBESITY AND CARDIOVASCULAR RISK
15 - HIGH RISK POPULATIONS
16 - LIPIDS AND EMERGING RISK FACTORS
17 - STROKE
18 - PERIPHERAL VASCULAR DISEASE
19 - HYPERTENSION AND CVD
20 - INFLAMMATION AS A CARDIOVASCULAR RISK FACTOR
21 - OXIDATIVE STRESS AND ANTIOXIDANTS
22 - HOMOCYSTEINE
23 - DIET
24 - FATTY ACIDS, OMEGA-3
25 - SMOKING, LIFESTYLE AND CVD
26 - THROMBOSIS AND CVD
27 - GLOBAL RISK ASSESSMENT
28 - INVASIVE AND NON-INVASIVE METHODS FOR GLOBAL RISK ASSESSMENT
29 - TREATMENT OF GLOBAL RISK VS INDIVIDUAL RISK
30 - ATHEROSCLEROSIS IN THE YOUNG
31 - DRUG INTERACTIONS
32 - PHARMACOGENETICS
33 - GENOMIC APPROACH TO RISK FACTOR IDENTIFICATION
34 - GENE AND CELL THERAPY
35 - GLOBAL RISK: INTERNATIONAL GUIDELINES AND RECOMMENDATIONS
36 - PHARMACOECONOMICS
37 - HOW TO TRANSFER GUIDELINES TO THE MEDICAL PRACTICE AND TO THE PUBLIC